Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s stock price hit a new 52-week low on Friday . The company traded as low as $9.05 and last traded at $9.60, with a volume of 228458 shares traded. The stock had previously closed at $9.44.
Astellas Pharma Stock Up 1.7 %
The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The firm has a market capitalization of $17.37 billion, a P/E ratio of 45.72 and a beta of 0.34. The firm's fifty day moving average price is $9.93 and its 200-day moving average price is $10.99.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. The firm had revenue of $3.11 billion during the quarter. As a group, equities research analysts forecast that Astellas Pharma Inc. will post 0.61 earnings per share for the current year.
Astellas Pharma Company Profile
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
